Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae298 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Kristina M Brooks und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora,…. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gilead Sciences, Inc, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Pregnant people with coronavirus disease 2019 (COVID-19) experience higher risk for severe disease and adverse pregnancy outcomes, but no pharmacokinetic (PK) data exist to support dosing of COVID-19 therapeutics during pregnancy. We report PK and safety data for intravenous remdesivir in pregnancy.
Methods
IMPAACT 2032 was a phase 4 prospective, open-label, nonrandomized opportunistic study of hospitalized pregnant and nonpregnant women receiving intravenous remdesivir as part of clinical care. Intensive PK sampling was performed on infusion days 3, 4, or 5 with collection of plasma and peripheral blood mononuclear cells (PBMCs). Safety data were recorded from first infusion through 4 weeks after last infusion and at delivery. Geometric mean ratios (GMR) (90% confidence intervals [CI]) of PK parameters between pregnant and nonpregnant women were calculated.
Results
Fifty-three participants initiated remdesivir (25 pregnant; median gestational age, 27.6 weeks; interquartile range, 24.9–31.0 weeks). Plasma exposures of remdesivir, its 2 major metabolites (GS-704277 and GS-441524), and the free remdesivir fraction were similar between pregnant and nonpregnant participants. Concentrations of the active triphosphate (GS-443902) in PBMCs increased 2.04-fold (90% CI, 1.35–3.03) with each additional infusion in nonpregnant versus pregnant participants. Three adverse events in nonpregnant participants were related to treatment (1 grade 3; 2 grade 2 resulting in treatment discontinuation). There were no treatment-related adverse pregnancy outcomes or congenital anomalies detected.
Conclusions
Plasma remdesivir PK parameters were comparable between pregnant and nonpregnant women, and no safety concerns were identified based on our limited data. These findings suggest no dose adjustments are indicated for intravenous remdesivir during pregnancy. Clinical Trials Registration NCT04582266.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Section of Pediatric Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
- Division of Pediatric Infectious Diseases, Stony Brook Children's Hospital, Stony Brook, New York, USA.
- Division of Pediatric Infectious Diseases, Division of Adult Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Division of Pediatric Infectious Diseases, BronxCare Health System, Bronx, New York, USA.
ORCID-Profile: Kristina M Brooks, Kristin Baltrusaitis, Sharon Nachman
Förderung
- Gilead Sciences, Inc
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIH HHS
- NICHD NIH HHS
- NIMH NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health
Zitieren
APA
Brooks, K. M., Baltrusaitis, K., Clarke, D. F., Nachman, S., Jao, J., Purswani, M. U., Agwu, A., Beneri, C., Deville, J. G., Powis, K. M., Stek, A. M., Eke, A. C., Shapiro, D. E., Capparelli, E., Greene, E., George, K., Yin, D. E., Jean-Philippe, P., Chakhtoura, N., …, & IMPAACT 2032 Study Team (2024). Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae298
Vancouver
Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, et al. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae298
BibTeX
@article{Brooks2024,
author = {Brooks, Kristina M and Baltrusaitis, Kristin and Clarke, Diana F and Nachman, Sharon and Jao, Jennifer and Purswani, Murli U and Agwu, Allison and Beneri, Christy and Deville, Jaime G and Powis, Kathleen M and Stek, Alice M and Eke, Ahizechukwu C and Shapiro, David E and Capparelli, Edmund and Greene, Elizabeth and George, Kathleen and Yin, Dwight E and Jean-Philippe, Patrick and Chakhtoura, Nahida and Bone, Frederic and Bacon, Kira and Johnston, Benjamin and Reding, Christina and Kersey, Kathryn and Humeniuk, Rita and Best, Brookie M and Mirochnick, Mark and Momper, Jeremiah D and IMPAACT 2032 Study Team, IMPAACT 2032 Study Team},
title = {Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae298}
}
EUVIMED